Complete absence of GLUT1 does not impair human terminal erythroid differentiation.

IF 7.4 1区 医学 Q1 HEMATOLOGY
Catarina Martins Freire, Nadine R King, Monika Dzieciatkowska, Daniel Stephenson, Pedro L Moura, Johannes G G Dobbe, Geert J Streekstra, Angelo D'Alessandro, Ashley M Toye, Timothy J Satchwell
{"title":"Complete absence of GLUT1 does not impair human terminal erythroid differentiation.","authors":"Catarina Martins Freire, Nadine R King, Monika Dzieciatkowska, Daniel Stephenson, Pedro L Moura, Johannes G G Dobbe, Geert J Streekstra, Angelo D'Alessandro, Ashley M Toye, Timothy J Satchwell","doi":"10.1182/bloodadvances.2024012743","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>The glucose transporter 1 (GLUT1) is 1 of the most abundant proteins within the erythrocyte membrane and is required for glucose and dehydroascorbic acid (vitamin C precursor) transport. It is widely recognized as a key protein for red cell structure, function, and metabolism. Previous reports highlighted the importance of GLUT1 activity within these uniquely glycolysis-dependent cells, in particular for increasing antioxidant capacity needed to avoid irreversible damage from oxidative stress in humans. However, studies of glucose transporter roles in erythroid cells are complicated by species-specific differences between humans and mice. Here, using CRISPR-mediated gene editing of immortalized erythroblasts and adult CD34+ hematopoietic progenitor cells, we generate committed human erythroid cells completely deficient in expression of GLUT1. We show that absence of GLUT1 does not impede human erythroblast proliferation, differentiation, or enucleation. This work demonstrates, to our knowledge, for the first time, generation of enucleated human reticulocytes lacking GLUT1. The GLUT1-deficient reticulocytes possess no tangible alterations to membrane composition or deformability in reticulocytes. Metabolomic analyses of GLUT1-deficient reticulocytes reveal hallmarks of reduced glucose import, downregulated metabolic processes and upregulated AMP-activated protein kinase signaling, alongside alterations in antioxidant metabolism, resulting in increased osmotic fragility and metabolic shifts indicative of higher oxidant stress. Despite detectable metabolic changes in GLUT1-deficient reticulocytes, the absence of developmental phenotype, detectable proteomic compensation, or impaired deformability comprehensively alters our understanding of the role of GLUT1 in red blood cell structure, function, and metabolism. It also provides cell biological evidence supporting clinical consensus that reduced GLUT1 expression does not cause anemia in GLUT1-deficiency syndrome.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470287/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024012743","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: The glucose transporter 1 (GLUT1) is 1 of the most abundant proteins within the erythrocyte membrane and is required for glucose and dehydroascorbic acid (vitamin C precursor) transport. It is widely recognized as a key protein for red cell structure, function, and metabolism. Previous reports highlighted the importance of GLUT1 activity within these uniquely glycolysis-dependent cells, in particular for increasing antioxidant capacity needed to avoid irreversible damage from oxidative stress in humans. However, studies of glucose transporter roles in erythroid cells are complicated by species-specific differences between humans and mice. Here, using CRISPR-mediated gene editing of immortalized erythroblasts and adult CD34+ hematopoietic progenitor cells, we generate committed human erythroid cells completely deficient in expression of GLUT1. We show that absence of GLUT1 does not impede human erythroblast proliferation, differentiation, or enucleation. This work demonstrates, to our knowledge, for the first time, generation of enucleated human reticulocytes lacking GLUT1. The GLUT1-deficient reticulocytes possess no tangible alterations to membrane composition or deformability in reticulocytes. Metabolomic analyses of GLUT1-deficient reticulocytes reveal hallmarks of reduced glucose import, downregulated metabolic processes and upregulated AMP-activated protein kinase signaling, alongside alterations in antioxidant metabolism, resulting in increased osmotic fragility and metabolic shifts indicative of higher oxidant stress. Despite detectable metabolic changes in GLUT1-deficient reticulocytes, the absence of developmental phenotype, detectable proteomic compensation, or impaired deformability comprehensively alters our understanding of the role of GLUT1 in red blood cell structure, function, and metabolism. It also provides cell biological evidence supporting clinical consensus that reduced GLUT1 expression does not cause anemia in GLUT1-deficiency syndrome.

GLUT1 的完全缺失不会影响人类末端红细胞的分化。
葡萄糖转运体 1(GLUT1)是红细胞膜上最丰富的蛋白质之一,是葡萄糖和脱氢抗坏血酸(维生素 C 前体)转运所必需的。它被公认为红细胞结构、功能和新陈代谢的关键蛋白。之前的报告强调了 GLUT1 在这些独特的依赖糖酵解的细胞中的重要性,特别是在提高抗氧化能力以避免人体受到氧化应激的不可逆损伤方面。然而,由于人类和小鼠的物种特异性差异,对葡萄糖转运体在红细胞中作用的研究变得非常复杂。在这里,我们利用 CRISPR 介导的永生红细胞和成人 CD34+ 造血祖细胞基因编辑技术,生成了完全缺乏 GLUT1 表达的人类红细胞。我们发现,GLUT1 的缺失不会阻碍人类红细胞的增殖、分化或去核。这项工作首次证明了缺乏 GLUT1 的无核人类网织红细胞的生成。缺乏 GLUT1 的网织红细胞的膜组成或网织红细胞的变形性没有明显改变。缺乏 GLUT1 的网状细胞的代谢组学分析显示了葡萄糖输入减少、代谢过程下调和 AMPK 信号上调的特征,同时还显示了抗氧化代谢的改变,导致渗透脆性增加和代谢转变,表明氧化应激增加。尽管在 GLUT1 缺乏的网状红细胞中可检测到代谢变化,但没有发育表型、可检测到的蛋白质组补偿或可变形性受损,这全面改变了我们对 GLUT1 在红细胞结构、功能和代谢中作用的认识。它还提供了支持临床共识的细胞生物学证据,即 GLUT1 表达减少不会导致 GLUT1 缺乏综合症患者贫血。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood advances
Blood advances Medicine-Hematology
CiteScore
12.70
自引率
2.70%
发文量
840
期刊介绍: Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信